Global Idiopathic Pulmonary Fibrosis (IPF) Market: Insights, Pipeline and Forecast (2021-2026)

The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan, India).
 
DELHI, India - Jan. 25, 2022 - PRLog -- ccording to Azoth Analytics research report, the global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271.3 Million in the year 2020 with North America leading the regional market share.

The primary driver of growth in the IPF market in recent years has been an increased use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favour of off-label pharmacological therapies and non-pharmacological treatments. Prior to the approval of these drugs, cheap corticosteroids and immunosuppressant's were used to treat IPF despite negative recommendations in evidence-based guidelines for general treatment.

The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include a rise in the prevalence of fibrotic disease and an increase in the geriatric population. In addition, a surge in demand for cost-effective drugs and the introduction of advanced treatment options propel market growth. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products is providing a thrust to the market growth.

Scope of the Report
  • The report presents the analysis of the Idiopathic Pulmonary Fibrosis market for the historical period of 2016-2020 and the forecast period of 2021-2026.
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone, Others).
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by End User (Hospital & Clinics, Academic and Research Organizations, Others).
  • The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Region (North America, Europe, Asia Pacific).
  • The attractiveness of the market has been presented by region, by Drug Class and by End User.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
  • The companies analysed in the report include AbbVie Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Boehringer Ingelheim, Merck KGaA, Gilead Sciences, Liminal Biosciences, Cipla, Galapagos NV, FibroGen, Medicinova Inc.

For more Information:

https://azothanalytics.com/report/healthcare-and-pharmaceutical/global-idiopathic-pulmonary-fibrosis-ipf-market-analysis-by-drug-type-end-user-by-region-by-country-2021-edition-market-insights-pipeline-and-forecast-with-impact-of-covid-19-2021-2026

Vishal Sharma

(Business Development Manager)

Address:  CS - 55, Third Floor, Ansal Plaza,

Vaishali, Ghaziabad

U.P., India

Mobile: +91-9873426288

Tel: +91-120- 4298235

Mail ID - info@azothanalytics.com

Contact
Vishal Sharma
info@azothanalytics.com
+91-9873426288
End
Email:***@azothanalytics.com Email Verified
Tags:Idiopathic Pulmonary Fibrosis
Industry:Reports
Location:Delhi - Delhi - India
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Azoth Analytics PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share